Science

Zantrene® (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a high dose, less cardiotoxic chemotherapeutic. The recent identification that Zantrane® is an highly potent FTO inhibitor has driven intense scientific and clinical interest in Zantrene as a rapidly translatable pharmaceutical able to target the m6A RNA methylation pathway. History of Zantrene® Zantrene was originally developed by Lederle Laboratories in the 1970s as a lower cardiotoxic alternative to the anthracycline chemotherapeutics. Lederle trialled Zantrene on…

Latest News

+

27 October 2021 – Race Oncology Limited (“Race”) is pleased to announce it has entered into a research collaboration with…

United States Patent No. 11,147,800 entitled COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF…

Race Oncology (“Race”) is pleased to announce that it has been issued a new patent (US 11,135,201) from the United…